The effect of β2AR modulation on PD risk has raised interest [94,95,96,123] because of the reduced vs. increased risk of developing PD in individuals using salbutamol (β2AR agonist) vs. propranolol (β2AR-antagonist), respectively [94,95]. The gene discussed is ADRB2; the disease is Parkinson disease.